Cognition Therapeutics presented Phase 2 SHIMMER data at the AD/PD 2026 conference in Copenhagen, Denmark, showing an 86 % slowing of decline on the Neuropsychiatric Inventory‑12 (NPI‑12) in patients with dementia with Lewy bodies (DLB) compared with placebo.
The result is striking because DLB psychosis has no approved disease‑modifying therapies and traditional antipsychotics can worsen motor symptoms. An 86 % reduction in neuropsychiatric decline suggests that zervimesine (CT1812) may address the behavioral and psychiatric symptoms that are most burdensome to patients and caregivers.
Earlier Phase 2 studies of zervimesine in Alzheimer’s disease and geographic atrophy reported an 82 % slowing in total NPI and a 91 % reduction in cognitive fluctuations. The current 86 % figure refines those earlier results and focuses on the NPI‑12, the most relevant subscale for DLB psychosis.
Following a Type C meeting with the FDA in January 2026, Cognition plans to advance zervimesine into a late‑stage program for DLB psychosis, with a scheduled meeting with the FDA Division of Psychiatry by mid‑2026. The data de‑risk the program and position the company to pursue the first disease‑modifying therapy for this unmet indication.
CMO Anthony Caggiano noted that the Phase 2 SHIMMER study demonstrated a robust treatment effect across neuropsychiatric, cognitive, motor, and global function domains, especially against DLB’s behavioral and psychiatric symptoms. CEO Lisa Ricciardi highlighted the favorable safety profile and oral dosing, which could make the drug tolerable for patients who cannot tolerate traditional antipsychotics.
Cognition’s balance sheet remains strong, with a current ratio of 6.44 and significant NIH grant funding that extends its cash runway. The company’s market capitalization is approximately $95–$96 million, giving it the financial flexibility to pursue the late‑stage development of zervimesine.
revised_sentiment_rating
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.